• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Basic Materials·002326.SZ
Share

Zhejiang Yongtai Technology Co.,Ltd. Stocks

CN¥ 18.88Last Updated 28.07.2026

Issuer Rating

3/7
Performance

Poor

Risk

Limited

Recommendation

Sell

Market Cap

CN¥ 2.46B

CN¥ 18.88
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zhejiang Yongtai Technology Co., Ltd., which commenced operations in 1999 and is headquartered in Linhai, China, primarily focuses on the innovation, production, and distribution of fluorine-based chemicals throughout the country. The company's offerings include fluorinated compounds essential for pharmaceutical applications, serving a wide array of medicinal fields such as anti-diabetic, antiviral, cardiovascular, quinolone-type antibacterial, and nervous system treatments. Additionally, they provide chemical intermediates utilized in the formulation of insecticides and fungicides. Furthermore, Zhejiang Yongtai Technology diversifies its portfolio with materials for liquid crystal displays, lithium-ion batteries, and various other energy-related products. They also extend custom manufacturing solutions to partners within the pharmaceutical and general chemical sectors.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.07.2026 19:38

"I've been through hell": July could be the worst month in history for Korean stocks

29.07.2026 19:23

Nuclear Resilience: Which Companies Made the List of the World's Most Valuable Mining Companies?

29.07.2026 18:09

Oil prices soared 7% after Trump's remarks about a U.S. retaliatory strike against Iran

29.07.2026 18:00

British "anti-tech stocks" surged to a historic high amid a chip sell-off

29.07.2026 17:42

"Bans Won't Help": Zuckerberg Urged the U.S. Not to Block Chinese Neural Networks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026